TheraRadar
Data updated: May 26, 2026

ABACAVIR SULFATE AND LAMIVUDINE (abacavir sulfate)

Infectious Disease Approved 2015-12-22
7
Indications
--
Phase 3 Trials
10
Years on Market

Details

Status
Discontinued
First Approved
2015-12-22
Routes
ORAL
Dosage Forms
TABLET, TABLET, FOR SUSPENSION

ABACAVIR SULFATE AND LAMIVUDINE Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
29 FDA actions from 2015 to 2025
Apr 2025 ORIGINAL
Update
Dec 2024 ORIGINAL
Update
Jun 2024 SUPPL
Label · Labeling

What ABACAVIR SULFATE AND LAMIVUDINE Treats

7 FDA approvals

Originally approved for its first indication in 2016 . Covers 7 distinct patient populations.

  • Other (7)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ABACAVIR SULFATE AND LAMIVUDINE FDA Label Details

Track ABACAVIR SULFATE AND LAMIVUDINE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.